FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
about
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerProfile of palbociclib in the treatment of metastatic breast cancerNovel Molecular Markers for Breast CancerImpact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancerCyclin Dependent Kinase 9 Inhibitors for Cancer TherapyOverview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to PaclitaxelDual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoCotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancerLincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation.Cell cycle proteins as promising targets in cancer therapyA gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.Palbociclib for the treatment of postmenopausal breast cancer - an update.5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.Liposarcoma: Multimodality Management and Future Targeted Therapies.Targeted adjuvant therapy in breast cancer.Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.Physiologically Based Pharmacokinetic Modeling of Palbociclib.Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition.Senescence and tumor suppression.Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
P2860
Q26738985-1203F5C8-86F6-4FAA-8AAD-125D933C94ADQ26747737-99F1D23A-BB9A-4EB5-BDD4-A21DA102010EQ26753160-CBC6F56F-88FA-4848-8234-0AD410092B9DQ28072793-C667439A-07A1-45B2-82B4-C2262560A6C8Q36015334-2753B6A2-F871-4E2F-8062-04D439D7705EQ36784065-F2063D26-8F3E-4307-BA4B-73267C3D4ED2Q37045421-9D9CD270-B4C1-4641-996D-BD1234A15FA9Q37075249-AE1391B2-0C41-4F18-815B-4CD03BF53EF6Q37151091-697AAC3D-BF41-4C3A-8B8A-8B5A0DD4E9A7Q37570653-3852C792-9BAE-4560-89F3-57EB071C3C9AQ37581544-DB537463-EAFB-45A6-A7E5-922988EB9F19Q37636710-A35EAD5D-7761-494C-A248-482454562BD3Q37649024-6ACECE5B-B556-43AA-BC8D-3BE21FC8942AQ37693690-2275B82E-5FBD-4E2E-869B-1803CBB6E346Q37708740-90813081-6AE6-4989-B3FB-B44B2CE3BAE3Q37746960-8C2A83C6-EB9F-47A5-BA78-428829035B76Q38662999-195F4C18-BC18-4D54-8EF6-E12AF21914E0Q38672387-91D8E76E-3430-47C2-AEF0-EE36E82219C8Q38686201-091F722B-6FAB-43DC-A9F7-BFEBC783DC83Q38692982-5CC9F45B-2CB4-414B-AA07-6E85BF035016Q38723383-DB749843-1154-4A79-A065-6DAEC9E7ECF9Q38739252-AA272BD6-957D-4FCA-A709-14696F9CEA9FQ38760366-3BD04439-1ABE-41FE-B572-AA3A1B670688Q38804149-9453A7DD-3296-4562-A97F-E8E4B756301EQ38824691-26E931AC-4178-4997-8B48-019C9F4F41CCQ38980703-BF260CF5-F120-4557-B6D1-5B95E7BE772AQ39190569-479C270C-1553-43FB-BEA7-3A9FD3A2F56AQ39289608-A9135290-DF20-412B-ADCD-DCE54053004FQ39311633-832D5D35-7DA3-4458-BEB0-96AE2323CA07Q39433738-0A509868-878A-4383-8EE2-310C4EB11B0AQ39612151-25CFD8D5-7690-4DBA-A522-2DFFD20A8E77Q39699318-8CC2B32A-AFB8-4748-803E-BD16D07764B7Q46132721-64D447E2-C549-4509-8921-51EFDAC00410Q47095669-7EE4B7EA-BC39-4E74-B38A-14C60627683BQ47106101-CE9D0324-963E-4909-814E-E4CF8F417EAEQ47169141-5D6F6A58-FF9B-4F44-864D-B87486DFEF6CQ47239499-0D0C9E3E-5040-43E6-9F58-C6B379A0C0A7Q47299171-D6F116B1-F69F-4A64-9363-A643F5F88A03Q47321016-7ACF458F-8FE6-4D24-AE47-55368F6C467DQ47362424-50464FDC-85FF-42D0-A42B-066C76D9092C
P2860
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
FDA Approval: Palbociclib for ...... tive Metastatic Breast Cancer.
@en
type
label
FDA Approval: Palbociclib for ...... tive Metastatic Breast Cancer.
@en
prefLabel
FDA Approval: Palbociclib for ...... tive Metastatic Breast Cancer.
@en
P2093
P1476
FDA Approval: Palbociclib for ...... tive Metastatic Breast Cancer.
@en
P2093
Amna Ibrahim
Amy Tilley
Erik Bloomquist
Geoffrey Kim
Jeanne Fourie Zirkelbach
Joyce Crich
Julia A Beaver
Laleh Amiri-Kordestani
Liang Zhao
P304
P356
10.1158/1078-0432.CCR-15-1185
P407
P577
2015-08-31T00:00:00Z